芪參益氣滴丸具有益氣通脈、活血止痛之功，是目前冠狀動脈粥樣硬化性心臟病臨床治療推薦用藥，但未經(jīng)過系統(tǒng)整理、歸納，缺乏相應(yīng)的指導(dǎo)性文件。為進(jìn)一步提高臨床醫(yī)生對該藥的認(rèn)識，更好地指導(dǎo)其臨床合理用藥，特邀請全國臨床與科研一線專家制訂本臨床應(yīng)用專家共識。本共識在系統(tǒng)檢索梳理芪參益氣滴丸上市以來的臨床及基礎(chǔ)研究證據(jù)的基礎(chǔ)上，采用國際臨床醫(yī)學(xué)專家共識研制方法，對芪參益氣滴丸疾病治療的優(yōu)勢環(huán)節(jié)、用藥方案與時機(jī)、劑量、療效特點、用藥安全及注意事項等問題等進(jìn)行了推薦或建議，通過了專家評審與論證，為指導(dǎo)芪參益氣滴丸的臨床合理用藥提供參考。該共識已通過中華中醫(yī)藥學(xué)會的審核，并進(jìn)行了發(fā)布，編號為GS/CACM 366—2024。

Qishenyiqi Dropping Pills, renowned for their efficacy in replenishing qi, invigorating blood circulation, and mitigating pain, are presently advocated for the clinical management of coronary atherosclerotic heart disease. Despite their therapeutic promise, there has been an absence of comprehensive synthesis or summarization of their applications, alongside a dearth of authoritative guidelines. To deepen clinicians' comprehension of this pharmaceutical and to steer its judicious clinical utilization, we have convened a panel of frontline clinical and research experts nationwide to craft this Expert Consensus on Clinical Application. This consensus is the product of meticulous scrutiny and analysis of clinical and fundamental research evidence accrued since the market introduction of Qishenyiqi Dropping Pills. Employing internationally recognized methodologies for formulating clinical medical expert consensus, it delineates recommendations on the therapeutic advantages, medication protocols and timing, dosage, efficacy profiles, safety, and precautions associated with Qishenyiqi Dropping Pills. Having been meticulously reviewed and validated by experts, this consensus serves as a beacon for the rational clinical deployment of Qishenyiqi Dropping Pills. Endorsed by the China Association of Chinese Medicine (CACM), this consensus has been formally promulgated under the document identifier GS/CACM 366-2024.

R972

國家自然科學(xué)基金面上項目（82374252）；上海市科學(xué)技術(shù)委員會“科技創(chuàng)新行動計劃”醫(yī)學(xué)創(chuàng)新研究專項（23Y31920200）